Cardiac Sudden Death in Psychiatric Patients

Chesney E Goodwin GM Fazel S. Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry. 2014;13:153–160.

Fazel S Wolf A Palm C Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: A 38-year total population study in Sweden. Lancet Psychiatry. 2014;1:44–54.

Crump C Sundquist K Winkleby MA Comorbidities and mortality in bipolar disorder: A Swedish national cohort study. JAMA Psychiatry. 2013;70:931–939.

Ifteni P Correll CU Burtea V Sudden unexpected death in schizophrenia: Autopsy findings in psychiatric inpatients. Schizophr Res. 2014;155:72–76.

Zivin K Yosef M Miller EM Associations between depression and all-cause and cause-specific risk of death: A retrospective cohort study in the Veterans Health Administration. J Psychosom Res. 2015;78(4):324–331.

Beach SR Kostis WJ Celano CM Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75:e441–e449.

Chung AK Chua SE . Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis. J Psychopharmacol. 2011;25:646–666.

Ng F Mammen OK Wilting I The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11:559–595.

Taylor D Paton C Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 11th ed. Chinchester (GB): John Wiley & Sons; 2012.

De Hert M Cohen D Bobes J Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011;10:138–151.

Ramanuj PP . Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications. Ment Health Fam Med. 2013;10:29–36.

Gilmer TP Dolder CR Folsom DP Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatr Serv. 2007;58:1007–1010.

Nielsen J le Quach P Emborg C 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010;122:356–366.

Tsutsumi C Uchida H Suzuki T The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective. Schizophr Res. 2011;130:40–46.

Yoshio T. [The trend for megadose polypharmacy in antipsychotic pharmacotherapy: A prescription survey conducted by the psychiatric clinical pharmacy research group]. Jpn J Psychiatry Neurol. 2012;114:690–695. Japanese.

Xiang YT Wang CY Si TM Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry. 2012;45:7–12.

Yatham LN Kennedy SH Parikh SV Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord. 2013;15:1–44.

Fleischhacker WW Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014;17:1083–1093.

Rabkin SW . Impact of age and sex on QT prolongation in patients receiving psychotropics. Can J Psychiatry. 2015;60(5):206–214.

Takeuchi H Suzuki T Remington G Antipsychotic polypharmacy and corrected QT interval: A systematic review. Can J Psychiatry. 2015;60(5):215–222.

Rotermann M Sanmartin C Hennessy D Prescription medication use by Canadians aged 6 to 79. Health Rep. 2014;25(6):3–9.